Strategic planning for the development of a novel therapy is critically important to reduce financial burdens, save time, and find the best, shortest path forwards. No two products will have the same pathway or same criterion for optimisation, but early, forward-looking planning can result in greater efficiency and a better understanding of key decisions and timepoints along the course of novel therapy development.
Biofilms for production
BackgroundResearchers have presented a novel method to promote biofilm formation. They believe their method can help to increase the efficiency of biocatalysis in biotechnological production processes and thus allow cost-effective recycling of waste, as well as carbon dioxide conversion into chemical building blocks and natural gas,
or amino acids.
Banks and policymakers driving climate change
BackgroundLast year, the G7 heads declared to end funding for the oil industry by the end of this year. At the COP27 in November, the WHO and United Nations renewed promises to redirect the hundreds of billions of dollars invested annually in fossil fuels to fund renewable energy initiatives.
Ultra-processed foods increase risk for cancer
Latest NewsBritish researchers have linked higher consumption of ultra-processed foods to an increased risk of developing and dying from cancer.
Lonza collaborates with Asher Biotherapeutics Inc
Latest NewsAsher Biotherapeutics Inc has expanded its manufacturing agreement with Lonza to include the manufacturing of AB248.
Wholistic approach to strategic consulting
BackgroundStrategic planning for the development of a novel therapy is critically important to reduce financial burdens, save time, and find the best, shortest path forwards. No two products will have the same pathway or same criterion for optimisation, but early, forward-looking planning can result in greater efficiency and a better understanding of key decisions and timepoints along the course of novel therapy development.
Evotec and Janssen team up in immunoncology
Latest NewsEvotec SE and Janssen Biotech Inc have agreed to co-develop targeted immuno-oncological therapies.
Evidence of deliberate climate damage
Latest NewsA new study adds weight to ongoing legal and political investigations against ExxonMobil for deliberate climate malfeasance.
Rewind Therapeutics extends Series A financing
Latest NewsWith Sunstone Life Siences A/S as a new investor, Belgian remyelination specialist Rewind Therapeutics has increased its 2018 Series A funding.
New polymer can stop biofilm formation
Latest NewsBritish researchers have created a new polymer material that may help to prevent urinary tract infections caused by catheters
Henkel buys FDCA from Avantium NV
Latest NewsBioplastics specialist Avantium N.V. has inked a 5-year agreement to supply Henkel with plant sugar based furandicarboxylic acid , a building block of PEF bioplastics.